Expands REVEAL Trial to FloridaWoodbridge, Ontario, Canada, September 12, 2011 - Pivotal Therapeutics Inc. (CNSX:PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease, today announced the expansion of its REVEAL Trial, “A randomized, Placebo-Controlled Study of VASCAZENTM in Patients With Deficient Blood Omega-3 Fatty Acid levels”, to a Florida-based study centre. The study was initiated this past June.“Expanding to a Clinical Study site in Florida is a strategic decision based upon Pivotal’s growing presence in the region and the overwhelmingly positive response from our network of cardiologists in the area anticipating the launch of VASCAZEN™” said Rachelle MacSweeney, President of Pivotal Therapeutics.The REVEAL Trial is a 200 patient, randomized, placebo-controlled, double-blind parallel study of Omega-3 deficient cardiovascular patients with elevated triglycerides. The study will assess the effectiveness of Pivotal’s lead therapeutic VASCAZEN™ by elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) Omega-3 fatty acids.“Findings from an earlier Open Label Study of VASCAZEN™ conducted by Pivotal indicate that over 80% of Study candidates’ initial blood results showed Omega-3 deficiency, using its companion OmegaScore™ Diagnostic Test.” said Dr. George Jackowski, Chairman, and Chief Scientific Officer. “I am extremely excited to share the full study results as part of Pivotal’s presentation at the Rodman & Renshaw conference on September 13th in New York City.”About Pivotal Therapeutics Inc.With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (CNSX: PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease. Pivotal Therapeutics' lead product VASCAZENTM is a prescription medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.VASCAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.https://the-wealth-report.blogspot.com/